FBRX
Forte Biosciences, Inc.Price
Daily candles with volume.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Aug 27. Recent filings are awards, exercises and tax withholding.
- InstitutionsBEARISH
Q3 2026: 0 added (0 new), 10 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$1.005 → −$1.090 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −14.3% to 1.63M shares. 1.5 days to cover, ≈7.7% of shares.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| FEDERATED HERMES, INC. | EXIT | $0.00 |
| VANGUARD CAPITAL MANAGEMENT LLC | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| BlackRock, Inc. | DOUBLED | $26.0M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $18.3M |
| Woodline Partners LP | DOUBLED | $15.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jul 2026| Date | Firm | Rating |
|---|---|---|
| Jul 28, 2026 | Barclays DOWNGRADE | Equal-Weight |
| Jul 21, 2026 | Barclays INITIATE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
GRYSKA DAVID W Director Aug 27, 2026 | TO ISSUER | 2,000 sh |
GRYSKA DAVID W Director Aug 27, 2026 | TO ISSUER | 18,353 sh |
VINCENT RICHARD G Director Aug 27, 2026 | TO ISSUER | 18,353 sh |
GRYSKA DAVID W Director Aug 27, 2026 | TENDER | 5,940 sh |
FINCK BARBARA K Director Aug 27, 2026 | TO ISSUER | 1,000 sh |
GRYSKA DAVID W Director Aug 27, 2026 | TO ISSUER | 2,000 sh |
Riley Antony A CHIEF FINANCIAL OFFICER Aug 27, 2026 | TO ISSUER | 750 sh |
FINCK BARBARA K Director Aug 27, 2026 | TO ISSUER | 166 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.09 | -$1.09–-$1.09 | -16.9% | $0.00 |
| Next Q | -$1.11 | -$1.11–-$1.11 | -13.4% | $0.00 |
| Current FY | -$4.48 | -$4.48–-$4.48 | -16.8% | $0.00 |
| Next FY | -$4.08 | -$5.91–-$2.89 | -0.9% | $0.00 |
Short side
FINRA· Aug 14, 2026| Aug 26, 2026 | Deletion | Resumed |
| Jul 9, 2026 | Volatility Pause | Resumed |
SecBot reports
15 filings · 1 bullish · 11 bearish · 1 mixed · 2 neutral- BEARISH SC 13G/ANov 13, 2026
Affinity Asset Advisors, LLC filed an amendment to Schedule 13G reporting a complete exit from…
Three passive institutional investors have now fully exited FBRX within weeks. Monitor for additional institutional selling and any potential conversion of remaining 13G filers to 13D activist…
- BEARISH SC 13G/ANov 13, 2026
MPM BioImpact LLC filed an amendment to Schedule 13G reporting a complete exit from Forte…
Two passive institutional holders have fully exited within 9 days. Monitor for additional 13G filings or insider selling that could signal broader institutional disengagement. The stock's high…
- BEARISH SC 13G/ANov 4, 2026
Tybourne Capital Management (HK) Ltd and related entities filed an amendment to Schedule 13G…
Monitor for any further insider or institutional selling that could signal broader loss of confidence. The exit by a notable healthcare-focused investor may weigh on sentiment, but the company's…
- BEARISH EFFECTSep 2, 2026
Forte Biosciences had four shelf registration statements (File Nos. 333-296425, 333-283814…
Expect a capital raise announcement within weeks as cash burn continues. The effectiveness of four separate shelves signals preparation for multiple or large offerings. Traders should watch for a…
All FBRX filing & press-release reports (15)
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 4, 2026
- EFFECT reportSep 2, 2026
- EFFECT reportSep 2, 2026
- 25-NSE reportAug 27, 2026
- 8-K reportJul 27, 2026
- EFFECT reportJun 11, 2026
- S-3/A reportJun 5, 2026
- S-3 reportJun 2, 2026
- 8-K reportJun 2, 2026
- 8-K reportMay 14, 2026
- 8-K reportApr 1, 2026
- 8-K reportApr 9, 2026
- 424B5 reportApr 8, 2026